手机:全球化背景下的“主动”选择——珠三角地区农民工手机消费的文化和心态解读

2005-2006 > Academic research: refereed > Publication in refereed journalVersion of RecordPublishe

MTT法检测平阳霉素对肿瘤细胞的药物活性研究

本文选用两种细胞株:人肝癌bEl-7402和肺腺癌l-342细胞,利用MTT法检测平阳霉素对两株细胞药物敏感性的探讨。将每毫升含10--6个细胞的培养液按(1/2)--n(n=0~7)梯度稀释,种于96孔板(100μl/孔),5%CO_2,37℃,培养34H,加MTT20μl(母液2Mg/Ml);再37%培养4H,加dMSO100μl溶解,测570nMOd值,结果贴壁生长的bEl-7402细胞的平均Od值为0.31(0.43~0.24),悬浮生长的l-342细胞的平均Od值为0.27(0.29~0.24),两者无显著性差别(P>0.05)。MTT甲月赞产物最大吸收波长为550~570nM,细胞浓度在一定范围内与甲月赞量近似成正比,MTT浓度以每孔4μg,孵育时间4小时为宜。将平阳霉素(母液1Mg/Ml)按(n=0~5)梯度稀释,加到每孔含有10000个细胞的培养板中,同上法测570nMOd值,结果显

农村村干部直选研究引发的若干理论问题

2003-2004 > Academic research: refereed > Publication in refereed journalVersion of RecordPublishe

Preparation and the Cytotoxicity of Conjugate Composed of Pingyangmycin and Monoclonal Antibody against Human Lung Cancer

用dEXTrAnT40为中介体的方法交联抗人肺腺癌单抗3d3和平阳霉素（A5），每克分子抗体可携带68克分子的药物，交联物中抗体活性仍能达到10-4水平，能较好地与靶细胞l-342结合。体外细胞毒实验，显示交联物和游离A5对靶细胞50%杀伤浓度分别为0.9μMOl/l和4.6μMOl/l，杀伤效果比游离A5强5倍多。单抗对靶细胞几乎没有杀伤作用；无关抗体交联物的作用也很弱。交联物和游离A5对非靶细胞MgC-803的杀伤作用无明显差别。结果提示MCAb3d3具有良好的导向作用，能携带结合的A5特异地杀伤肺腺癌l-342细胞，可作为临床抗肿瘤药物导向治疗的一种载体。The conjugate of pingyangmycin (A5) and monclonal antibody3D3(MCAb3D3) against human lung cancer was prepared with dextran T40 as the mediator.The molar ratio of A5 McAb3D3 in the conjugate was 68:1 the titer of the conjugate was remained at 10-4.In vitro,the cytotoxicity of the conjugate and Free A5 yieded IC50 of 0.9μmol/L and 4.6μmol/L,respectivel.The conjugate was Fivetimes stronger than Free A5 The cytotoxicity of the conjugate on non-target cells MGc-803 was much weaker and similar to that of.Free A5.There is no doubt that MCAb3D3 had targeting activity and could kill or damage tumor cells speciFically and could be taken as a kind of vector in studies of clinical targeting therapy

Preliminary pharmacodynamic study of STS as an adjuvant ofthe chemotherapy drugs in Vitro and in Vivo

目的：研究硫代硫酸钠（STS）是否能在体内、外作为化疗药的辅药。方法：应用MTT法研究STS分别与AdM、MMC和CddP等6种抗癌单药合用时对bEl-7402和MgC80-3细胞的细胞毒性作用；应用小鼠肝癌腹水瘤（H22）模型判断STS与AdM等3种药合用时的抗癌疗效；20例人原发性肝癌病人肝动脉插管化疗（AdM、MMC和CddP）前30MIn静脉推注STS（125~25g/M2）考察STS作为化疗药辅药的作用。结果：除了CddP以外，STS（500μg/Ml）与AdM等5种抗癌单药合用时对抗癌药的抗肿瘤细胞活性无明显影响（P＞005）。当不同剂量STS（350Mg/kg、35Mg/kg）分别与AdM（6Mg/kg）、MMC（14Mg/kg）和CddP（45Mg/kg）合用或仅这3种化疗药合用时，这3组腹水瘤小鼠的存活期比对照组者显著延长（P＜0001），但3组之间无明显区别（P＞005）。人肝癌肝动脉插管化疗时，STS与AdM、MMC和CddP抗癌药合用，肝癌治疗总有效率达60%，且可减少70%病人的恶心、呕吐等副作用。结论：在体内，低浓度的STS（125~25g/M2）可与AdM，MM？Objective: To study whether sodium thiosulfate (STS) can be used as an adjuvant of the chemotherapy drugs. Methods: The cytotoxicity of STS combined with ADM, MMC, CDDP, 5Fu, MTX and VCR (1PPC/ml) respectively on the cells of BEL7402 and MGc803 was studied by MTT test in vitro.The ascitic hepatoma (H22) in mice were adopted to determine the anticancer effect of STS adjuvant of ADMMMC and CDDP.Being treated with STS(12525 g/m2) 30 min before drug administration,20 patients of hepatocellular carcinoma (HCC) were carried on transcatheter arterial chemoembolization with ADMMMC and CDDP to observe the adjuvant effect of STS. Results: The anticancer activity of ADM and the other agents respectively adjuvant with STS (500 g/ml) were not obviously influented (P >005), but that for CDDP was influented .It was proven that the survival time of ascitic hepatoma treated with ADM (6 mg/kg),MMC (14 mg/kg) and CDDP (45 mg/kg) alone or three drugs in addition to STS (350 mg/kg,35 mg/kg) respectively was not significantly different (P >005).The survival time of each groups was significantly longer than that of control group (P< 0001).It have also been proven that STS adjuvant of ADM, MMC and CDDP was not decreased the chemotherapry effect (RR=60%) by transcatheter arterial chemoembolization in HCC, simultaneously it alleviated the nausea and vomiting in 70%patients. Conclusion: The study provides evidence that in vivo, STS (12525 g/m2) can be used as an adjuvant of chemotherapy drugs,such as ADM,MMC, including CDDP, and so on , for decreasing nausea and vomiting effects, espacially for transcatheter chemotherapy .福建省“八五”肝癌攻关课

用荷瘤裸鼠模型研制抗人肝癌单克隆抗体

1985年Watanabe等报道:用去胸腺载瘤小鼠的脾细胞与小鼠骨髓瘤细胞SP 2/0融合获得抗结肠癌单克隆抗体之后,利用荷瘤裸鼠模型成功研制抗人肿瘤单抗的报道已相继出现:但所获单抗多为IgM,IgG类的单抗得率不高,本工作采用多次手术大部切除瘤块的方法延长荷瘤裸鼠的成活期,获得一株抗人肝癌IgG类单抗、其研制过程和结果报道如下

李永康膏滋对小鼠胸腺端粒酶活性等免疫功能的影响

通过臭氧(O_3)致小鼠衰老模型,对各组抗衰老实验小鼠的生理和免疫功能进行检测,采用端粒重复序列分析(TRAP)方法检测衰老小鼠胸腺组织的端粒酶活性。李永康膏滋能使衰老小鼠爬绳、游泳和抗冻能力增强(P<0.05或P<0.01),血清总IgG浓度提高(P<0.01),脚掌发疱增重明显(P<0.01),胸腺指数增加(P<0.05或P<0.01);并使衰老小鼠胸腺端粒酶活性增强。表明李氏膏滋有延缓臭氧致小鼠衰老的作用,提高衰老小鼠体液和细胞免疫功能。使衰老小鼠胸腺端粒酶活性增强可能与该器官富含活化的淋巴细胞有关。教育部厦门大学细胞生物学和肿瘤细胞工程重点实验室开放研究基

抗人肺癌单克隆抗体(3D3)的研制及其特性鉴定

本文用人肺腺癌组织免疫的BALB/c小鼠脾细胞与小鼠骨髓瘤Sp2/0细胞融合,获得1株单克隆抗体(McAb 3D3)。Ig类测定为IgG_1型。杂交瘤培养上清液和腹水的效价分别为1∶10~3～10~4和1∶10~6。采用间接免疫荧光法(IFA)观察到McAb3D3主要与肺腺癌细胞株A549和L342反应,与其它组织肿瘤细胞株没有反应。ABC免疫酶染色试验显示McAb3D3主要与肺腺癌组织反应,与正常肺组织没有反应

抗肺癌单克隆抗体在裸鼠移植瘤中的放射免疫显像

抗肺癌单克隆抗体在裸鼠移植瘤中的放射免疫显像俞浩，瞿跃进，颜江华，盛荣宗，林月华俞丹，苏新辉，毛利娜，苏金华，杨善民我们用131I标记抗肺癌单克隆抗体（MCAb3d3）在移植人肺腺癌裸鼠中进行显像，并研究裸鼠体内生物学分布，现将结果报道如下.材料和方..

Photodynamic And Cytotoxicity of Sulphonated Aluminium Phthalocyanine on MGc 803 Cell Lines

近年来血卟啉衍生物（HEMATOPOrPHyrIndErIVATIVE，HPd）在基础医学与临床上对癌细胞的较强杀伤作用研究已取得了不少进展，但它不易从血清中制备，在肝脏有太多积聚，对体表皮肤有光毒反应等缺点，同时它的主吸收峰在紫光波段（405nM）...SulFonated aluminium phthalocyanine (ALSPc) was synthesizedvia sulFonating aluminum phthalocyanine.The product is a mixture with diFFerent sulFonic groups on the macrocycle of phthalocynine molecule,and was used as photosensitizer in this work.A dye laser driven by an argon laser was employed to provide monocolor light,which was used as radiation source in the photosensitizing investigation.The number of living cells survived From radiation was detected by MTT method.The photosensitization eFFects of both ALSPc and HPD (hematoporphyrin deriviatives)were compared with each other.When the concentration of ALSPc was 10.76 μg/mL,and the energy density of light used was 5 J/cm 2,FiFty percent of gastric cancer cell were killed;however,the concentration of HPD at 24.83 μg/mL was reguired For getting the same result.It was Found that the absorbance of ALSPc at 677 nm was 19 times than that of HPD at 630 nm,maybe implying that ealue ALSPc is a more eFFective photosensitizer in photodynamic treatment (PDT) of cancer